This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MEIP MEI Pharma (MEIP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About MEI Pharma Stock (NASDAQ:MEIP) Get MEI Pharma alerts:Sign Up Key Stats Today's Range$2.85▼$3.2550-Day Range$2.78▼$5.2852-Week Range$1.92▼$9.00Volume3.98 million shsAverage Volume919,067 shsMarket Capitalization$104.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MEI Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer. The company’s lead programs include pracinostat, an oral histone deacetylase inhibitor being studied in combination with azacitidine for acute myeloid leukemia, ME-401 (umbralisib), a next-generation PI3K-delta inhibitor targeting various B-cell malignancies, and CPI-1205, an EZH2 inhibitor under evaluation in both hematologic and solid tumor indications. MEI Pharma’s pipeline reflects a strategic emphasis on epigenetic and signal-transduction pathways that have the potential to address critical unmet needs in oncology. Headquartered in San Diego, California, MEI Pharma operates in key clinical research geographies across North America and Europe, collaborating with academic institutions and contract research organizations to advance its clinical trials. The company leverages a combination of in-house discovery capabilities and external partnerships to optimize its development candidates, with a focus on robust study designs and expedited regulatory pathways where warranted. MEI Pharma’s approach aims to move promising compounds efficiently through early- to late-stage trials and ultimately into commercialization. MEI Pharma was incorporated in the early 2000s and has since evolved into a specialized oncology developer with a seasoned management team. Vamsi N. Mootha, Ph.D., serves as President and Chief Executive Officer, leading a team of industry veterans with backgrounds spanning clinical development, regulatory affairs, and commercial strategy. With a commitment to addressing challenging cancers through targeted therapies, MEI Pharma continues to build on its scientific expertise as it progresses its pipeline toward potential regulatory approval and broader patient access.AI Generated. May Contain Errors. Read More Receive MEIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MEIP Stock News HeadlinesMEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’September 11, 2025 | theglobeandmail.comMEI Pharma to change name to Lite StrategySeptember 10, 2025 | msn.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 22 at 1:00 AM | Profits Run (Ad)MEI Pharma Secures Loan Agreement with BitGo PrimeSeptember 4, 2025 | msn.comMEI Pharma Welcomes New Board Member Joshua RiezmanAugust 11, 2025 | theglobeandmail.comMEI Pharma files to sell 25.3M shares of common stock for holdersAugust 7, 2025 | msn.comMEI Pharma’s Strategic Shift with Litecoin TreasuryJuly 25, 2025 | theglobeandmail.comMEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National ExchangeJuly 22, 2025 | businesswire.comSee More Headlines MEIP Stock Analysis - Frequently Asked Questions How were MEI Pharma's earnings last quarter? MEI Pharma, Inc. (NASDAQ:MEIP) announced its earnings results on Tuesday, May, 13th. The company reported ($0.39) EPS for the quarter. When did MEI Pharma's stock split? MEI Pharma shares reverse split before market open on Monday, April 17th 2023.The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of MEI Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that MEI Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL). Company Calendar Last Earnings5/13/2025Today5/22/2026Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MEIP Previous SymbolNASDAQ:MSHL CIK1262104 Webwww.meipharma.com Phone(858) 369-7100Fax302-655-5049Employees100Year Founded2000Profitability EPS (Trailing Twelve Months)($4.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$17.78 million Net MarginsN/A Pretax MarginN/A Return on Equity-77.00% Return on Assets-64.79% Debt Debt-to-Equity RatioN/A Current Ratio16.78 Quick Ratio16.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$6.25 per share Price / Cash Flow0.51 Book Value$4.96 per share Price / Book0.64Miscellaneous Outstanding Shares32,838,000Free Float31,813,000Market Cap$104.72 million OptionableOptionable Beta0.38 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:MEIP) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MEI Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
